Safety and Efficacy Study of Intrasphincteric Autologous Myoblast Injection to Treat Stress Urinary Incontinence

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Stress Urinary Incontinence
Interventions
BIOLOGICAL

Transurethral intrasphincteric autologous myoblast implantation

Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.

Trial Locations (1)

1000

University Medical Center Ljubljana, Dept. of Gynecology, Ljubljana

Sponsors
All Listed Sponsors
collaborator

Innovacell Biotechnologie AG

INDUSTRY

lead

University Medical Centre Ljubljana

OTHER